Moderna says it is working on a Hantavirus vaccine

Moderna has announced it is developing a vaccine targeting Hantavirus, a rare but potentially fatal rodent-borne pathogen that causes hantavirus pulmonary syndrome. The company did not disclose a timeline or clinical stage for the program.

The move aligns with Moderna's broader mRNA platform strategy of expanding beyond COVID-19 into infectious diseases with limited or no existing vaccine options. Hantavirus has no approved vaccine in Western markets, making it a clear white-space target for the technology.